Author: Ravi Shankar

ENDEAVOUR ANNOUNCES TRANSACTION IN OWN SHARES

London, 20 October 2026 – Endeavour Mining plc (LSE:EDV, TSX:EDV, OTCQX:EDVMF) (“the Company”) announces it has purchased the following number of its ordinary shares of USD 0.01 each from Stifel Nicolaus Europe Limited.

Aggregated information

Date of Purchase	Aggregate number of ordinary shares of USD 0.01 each purchased:	Lowest price paid per share (GBp):	Highest price paid per share (GBp):	Volume weighted average price paid per share (GBp):
14 Oct 2026	9,045	3,956.00	4,141.00	4,008.39
15 Oct 2026	32,308	3,941.29	4,069.00	3,991.62
16 Oct 2026	39,432	4,110.00	4,220.00	4,167.00

Following the cancellation of the repurchased shares, the Company will have no ordinary shares in treasury and 241,544,937 ordinary shares in issue. Therefore, the total voting rights in the Company will be 241,544,937. This figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

These share purchases form part of the Company’s buy-back programme announced on 20 March 2026.

Transaction details

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), the table below contains detailed information of the individual trades made by Stifel Nicolaus Europe Limited as part of the buyback programme.

Schedule of purchases

Shares purchased:                Endeavour Mining plc (ISIN: GB00BL6K5J42)

Date of purchases:                Week commencing 12 October 2026

Investment firm:                  Stifel Nicolaus Europe Limited

Individual transactions

Transaction date and time	Volume	Price (GBp)	Trading Venue
14 Oct 2026, 08:06 AM	112	4,137.00	LSE
14 Oct 2026, 08:07 AM	123	4,131.00	LSE
14 Oct 2026, 08:09 AM	114	4,131.00	LSE
14 Oct 2026, 08:11 AM	115	4,127.00	LSE
14 Oct 2026, 08:15 AM	135	4,135.00	LSE
14 Oct 2026, 08:16 AM	145	4,141.00	LSE
14 Oct 2026, 01:30 PM	54	4,127.00	LSE
14 Oct 2026, 01:30 PM	75	4,127.00	LSE
14 Oct 2026, 02:33 PM	129	4,063.00	LSE
14 Oct 2026, 02:33 PM	105	4,073.00	LSE
14 Oct 2026, 02:33 PM	30	4,073.00	LSE
14 Oct 2026, 02:33 PM	129	4,067.00	LSE
14 Oct 2026, 02:34 PM	31	4,064.00	LSE
14 Oct 2026, 02:34 PM	82	4,064.00	LSE
14 Oct 2026, 02:34 PM	129	4,063.00	LSE
14 Oct 2026, 02:34 PM	26	4,062.00	LSE
14 Oct 2026, 02:34 PM	43	4,062.00	LSE
14 Oct 2026, 02:34 PM	26	4,062.00	LSE
14 Oct 2026, 02:34 PM	26	4,061.00	LSE
14 Oct 2026, 02:35 PM	126	4,049.00	LSE
14 Oct 2026, 02:40 PM	8	4,037.00	LSE
14 Oct 2026, 02:40 PM	32	4,037.00	LSE
14 Oct 2026, 02:40 PM	80	4,037.00	LSE
14 Oct 2026, 02:40 PM	11	4,037.00	LSE
14 Oct 2026, 02:40 PM	61	4,036.00	LSE
14 Oct 2026, 02:40 PM	29	4,036.00	LSE
14 Oct 2026, 02:40 PM	24	4,036.00	LSE
14 Oct 2026, 02:40 PM	9	4,036.00	LSE
14 Oct 2026, 02:46 PM	114	4,019.00	LSE
14 Oct 2026, 02:46 PM	136	4,019.00	LSE
14 Oct 2026, 02:47 PM	125	4,017.00	LSE
14 Oct 2026, 02:47 PM	3	4,020.00	LSE
14 Oct 2026, 02:47 PM	63	4,020.00	LSE
14 Oct 2026, 02:47 PM	62	4,020.00	LSE
14 Oct 2026, 02:48 PM	128	4,020.00	LSE
14 Oct 2026, 02:48 PM	115	4,020.00	LSE
14 Oct 2026, 02:48 PM	125	4,019.00	LSE
14 Oct 2026, 02:49 PM	125	4,017.00	LSE
14 Oct 2026, 02:49 PM	26	4,015.00	LSE
14 Oct 2026, 02:51 PM	123	4,017.00	LSE
14 Oct 2026, 02:51 PM	111	4,018.00	LSE
14 Oct 2026, 02:53 PM	93	4,015.00	LSE
14 Oct 2026, 02:53 PM	32	4,015.00	LSE
14 Oct 2026, 02:59 PM	81	4,009.00	LSE
14 Oct 2026, 02:59 PM	32	4,009.00	LSE
14 Oct 2026, 02:59 PM	75	4,008.00	LSE
14 Oct 2026, 02:59 PM	44	4,008.00	LSE
14 Oct 2026, 03:32 PM	131	3,977.00	LSE
14 Oct 2026, 03:32 PM	133	3,976.00	LSE
14 Oct 2026, 03:35 PM	135	3,984.00	LSE
14 Oct 2026, 03:35 PM	132	3,991.00	LSE
14 Oct 2026, 03:36 PM	132	3,987.00	LSE
14 Oct 2026, 03:37 PM	129	3,982.00	LSE
14 Oct 2026, 03:38 PM	114	3,984.00	LSE
14 Oct 2026, 03:38 PM	114	3,989.00	LSE
14 Oct 2026, 03:38 PM	131	3,986.00	LSE
14 Oct 2026, 03:39 PM	116	3,975.00	LSE
14 Oct 2026, 03:41 PM	132	3,986.00	LSE
14 Oct 2026, 03:44 PM	136	4,004.00	LSE
14 Oct 2026, 03:45 PM	15	4,000.00	LSE
14 Oct 2026, 03:45 PM	116	4,000.00	LSE
14 Oct 2026, 03:47 PM	137	3,997.00	LSE
14 Oct 2026, 03:47 PM	134	3,995.00	LSE
14 Oct 2026, 03:49 PM	133	3,995.00	LSE
14 Oct 2026, 03:50 PM	112	3,985.00	LSE
14 Oct 2026, 03:51 PM	121	3,985.00	LSE
14 Oct 2026, 03:52 PM	120	3,986.00	LSE
14 Oct 2026, 03:52 PM	3	3,988.00	LSE
14 Oct 2026, 03:52 PM	7	3,988.00	LSE
14 Oct 2026, 03:52 PM	12	3,988.00	LSE
14 Oct 2026, 03:52 PM	100	3,988.00	LSE
14 Oct 2026, 03:53 PM	123	3,987.00	LSE
14 Oct 2026, 04:06 PM	112	3,976.00	LSE
14 Oct 2026, 04:06 PM	132	3,972.00	LSE
14 Oct 2026, 04:07 PM	137	3,967.00	LSE
14 Oct 2026, 04:07 PM	122	3,962.00	LSE
14 Oct 2026, 04:07 PM	126	3,961.00	LSE
14 Oct 2026, 04:07 PM	117	3,961.00	LSE
14 Oct 2026, 04:07 PM	125	3,960.00	LSE
14 Oct 2026, 04:07 PM	15	3,958.00	LSE
14 Oct 2026, 04:07 PM	104	3,958.00	LSE
14 Oct 2026, 04:07 PM	104	3,958.00	LSE
14 Oct 2026, 04:08 PM	9	3,957.00	LSE
14 Oct 2026, 04:08 PM	97	3,957.00	LSE
14 Oct 2026, 04:08 PM	17	3,957.00	LSE
14 Oct 2026, 04:08 PM	54	3,956.00	LSE
14 Oct 2026, 04:08 PM	76	3,956.00	LSE
14 Oct 2026, 04:11 PM	137	3,963.00	LSE
14 Oct 2026, 04:11 PM	1	3,960.00	LSE
14 Oct 2026, 04:11 PM	123	3,962.00	LSE
14 Oct 2026, 04:11 PM	19	3,958.00	LSE
14 Oct 2026, 04:11 PM	100	3,958.00	LSE
14 Oct 2026, 04:11 PM	89	3,958.00	LSE
14 Oct 2026, 04:11 PM	17	3,958.00	LSE
14 Oct 2026, 04:12 PM	48	3,958.00	LSE
14 Oct 2026, 04:13 PM	111	3,964.00	LSE
14 Oct 2026, 04:13 PM	34	3,965.00	LSE
14 Oct 2026, 04:13 PM	55	3,965.00	LSE
14 Oct 2026, 04:13 PM	34	3,964.00	LSE
14 Oct 2026, 04:14 PM	125	3,966.00	LSE
14 Oct 2026, 04:14 PM	135	3,965.00	LSE
14 Oct 2026, 04:14 PM	74	3,965.00	LSE
14 Oct 2026, 04:15 PM	116	3,973.00	LSE
14 Oct 2026, 04:16 PM	18	3,971.00	LSE
14 Oct 2026, 04:18 PM	40	3,975.00	LSE
14 Oct 2026, 04:18 PM	15	3,975.00	LSE
14 Oct 2026, 04:18 PM	56	3,975.00	LSE
14 Oct 2026, 04:18 PM	61	3,975.00	LSE
15 Oct 2026, 07:00 AM	15,400	3,941.29	TSX
15 Oct 2026, 08:03 AM	134	3,957.00	LSE
15 Oct 2026, 08:03 AM	114	3,952.00	LSE
15 Oct 2026, 08:04 AM	134	3,953.00	LSE
15 Oct 2026, 08:04 AM	130	3,951.00	LSE
15 Oct 2026, 08:04 AM	118	3,957.00	LSE
15 Oct 2026, 08:05 AM	126	3,966.00	LSE
15 Oct 2026, 08:07 AM	134	3,995.00	LSE
15 Oct 2026, 08:07 AM	132	3,993.00	LSE
15 Oct 2026, 08:07 AM	129	3,990.00	LSE
15 Oct 2026, 08:08 AM	124	3,996.00	LSE
15 Oct 2026, 08:08 AM	42	3,997.00	LSE
15 Oct 2026, 08:08 AM	94	3,997.00	LSE
15 Oct 2026, 08:12 AM	113	4,031.00	LSE
15 Oct 2026, 08:12 AM	128	4,030.00	LSE
15 Oct 2026, 08:18 AM	113	4,030.00	LSE
15 Oct 2026, 08:20 AM	133	4,023.00	LSE
15 Oct 2026, 08:21 AM	120	4,020.00	LSE
15 Oct 2026, 08:23 AM	76	4,012.00	LSE
15 Oct 2026, 08:23 AM	42	4,012.00	LSE
15 Oct 2026, 08:26 AM	132	4,026.00	LSE
15 Oct 2026, 08:27 AM	132	4,023.00	LSE
15 Oct 2026, 08:29 AM	15	4,020.00	LSE
15 Oct 2026, 08:29 AM	119	4,020.00	LSE
15 Oct 2026, 08:32 AM	132	4,040.00	LSE
15 Oct 2026, 08:33 AM	118	4,031.00	LSE
15 Oct 2026, 08:34 AM	114	4,024.00	LSE
15 Oct 2026, 08:36 AM	125	4,025.00	LSE
15 Oct 2026, 08:38 AM	116	4,037.00	LSE
15 Oct 2026, 08:47 AM	122	4,044.00	LSE
15 Oct 2026, 08:48 AM	111	4,041.00	LSE
15 Oct 2026, 08:51 AM	124	4,046.00	LSE
15 Oct 2026, 08:51 AM	12	4,046.00	LSE
15 Oct 2026, 08:51 AM	118	4,046.00	LSE
15 Oct 2026, 08:54 AM	119	4,049.00	LSE
15 Oct 2026, 08:54 AM	23	4,049.00	LSE
15 Oct 2026, 08:54 AM	58	4,049.00	LSE
15 Oct 2026, 08:54 AM	14	4,049.00	LSE
15 Oct 2026, 08:54 AM	14	4,049.00	LSE
15 Oct 2026, 08:54 AM	16	4,049.00	LSE
15 Oct 2026, 08:54 AM	133	4,043.00	LSE
15 Oct 2026, 09:00 AM	137	4,055.00	LSE
15 Oct 2026, 09:00 AM	119	4,054.00	LSE
15 Oct 2026, 09:21 AM	136	4,059.00	LSE
15 Oct 2026, 09:29 AM	119	4,064.00	LSE
15 Oct 2026, 09:39 AM	121	4,065.00	LSE
15 Oct 2026, 09:42 AM	137	4,062.00	LSE
15 Oct 2026, 09:49 AM	122	4,062.00	LSE
15 Oct 2026, 09:49 AM	80	4,063.00	LSE
15 Oct 2026, 09:50 AM	129	4,067.00	LSE
15 Oct 2026, 09:51 AM	112	4,069.00	LSE
15 Oct 2026, 09:51 AM	119	4,067.00	LSE
15 Oct 2026, 09:57 AM	112	4,060.00	LSE
15 Oct 2026, 09:57 AM	131	4,054.00	LSE
15 Oct 2026, 09:59 AM	135	4,050.00	LSE
15 Oct 2026, 10:04 AM	112	4,060.00	LSE
15 Oct 2026, 10:04 AM	123	4,060.00	LSE
15 Oct 2026, 10:05 AM	126	4,058.00	LSE
15 Oct 2026, 10:05 AM	133	4,052.00	LSE
15 Oct 2026, 10:06 AM	116	4,051.00	LSE
15 Oct 2026, 10:11 AM	131	4,053.00	LSE
15 Oct 2026, 10:12 AM	132	4,051.00	LSE
15 Oct 2026, 10:14 AM	119	4,056.00	LSE
15 Oct 2026, 10:15 AM	111	4,054.00	LSE
15 Oct 2026, 10:19 AM	116	4,054.00	LSE
15 Oct 2026, 10:24 AM	137	4,058.00	LSE
15 Oct 2026, 10:29 AM	133	4,058.00	LSE
15 Oct 2026, 10:32 AM	99	4,056.00	LSE
15 Oct 2026, 10:32 AM	36	4,056.00	LSE
15 Oct 2026, 10:34 AM	116	4,058.00	LSE
15 Oct 2026, 10:37 AM	134	4,059.00	LSE
15 Oct 2026, 10:40 AM	121	4,056.00	LSE
15 Oct 2026, 10:40 AM	85	4,055.00	LSE
15 Oct 2026, 10:40 AM	39	4,055.00	LSE
15 Oct 2026, 10:44 AM	129	4,056.00	LSE
15 Oct 2026, 10:44 AM	124	4,055.00	LSE
15 Oct 2026, 10:48 AM	128	4,050.00	LSE
15 Oct 2026, 10:48 AM	5	4,050.00	LSE
15 Oct 2026, 10:51 AM	121	4,051.00	LSE
15 Oct 2026, 10:53 AM	112	4,048.00	LSE
15 Oct 2026, 10:56 AM	9	4,049.00	LSE
15 Oct 2026, 10:56 AM	111	4,049.00	LSE
15 Oct 2026, 11:00 AM	136	4,046.00	LSE
15 Oct 2026, 11:03 AM	121	4,051.00	LSE
15 Oct 2026, 11:03 AM	117	4,049.00	LSE
15 Oct 2026, 11:08 AM	123	4,042.00	LSE
15 Oct 2026, 11:08 AM	12	4,038.00	LSE
15 Oct 2026, 11:08 AM	24	4,038.00	LSE
15 Oct 2026, 11:08 AM	32	4,038.00	LSE
15 Oct 2026, 11:11 AM	112	4,037.00	LSE
15 Oct 2026, 11:12 AM	119	4,037.00	LSE
15 Oct 2026, 11:18 AM	22	4,044.00	LSE
15 Oct 2026, 11:18 AM	129	4,044.00	LSE
15 Oct 2026, 11:18 AM	108	4,044.00	LSE
15 Oct 2026, 11:19 AM	136	4,038.00	LSE
15 Oct 2026, 11:23 AM	54	4,043.00	LSE
15 Oct 2026, 11:23 AM	60	4,043.00	LSE
15 Oct 2026, 11:26 AM	117	4,044.00	LSE
15 Oct 2026, 11:26 AM	141	4,043.00	LSE
15 Oct 2026, 11:28 AM	123	4,043.00	LSE
15 Oct 2026, 11:31 AM	94	4,046.00	LSE
15 Oct 2026, 11:31 AM	36	4,046.00	LSE
15 Oct 2026, 11:31 AM	121	4,044.00	LSE
15 Oct 2026, 11:35 AM	41	4,044.00	LSE
15 Oct 2026, 11:35 AM	86	4,044.00	LSE
15 Oct 2026, 11:40 AM	161	4,051.00	LSE
15 Oct 2026, 11:40 AM	17	4,051.00	LSE
15 Oct 2026, 11:42 AM	113	4,051.00	LSE
15 Oct 2026, 11:44 AM	115	4,050.00	LSE
15 Oct 2026, 11:52 AM	119	4,060.00	LSE
15 Oct 2026, 11:53 AM	137	4,058.00	LSE
15 Oct 2026, 11:54 AM	134	4,058.00	LSE
15 Oct 2026, 12:00 PM	135	4,058.00	LSE
15 Oct 2026, 12:00 PM	7	4,058.00	LSE
15 Oct 2026, 12:00 PM	12	4,058.00	LSE
15 Oct 2026, 12:00 PM	100	4,058.00	LSE
15 Oct 2026, 12:08 PM	4	4,056.00	LSE
15 Oct 2026, 12:08 PM	84	4,056.00	LSE
15 Oct 2026, 12:08 PM	46	4,056.00	LSE
15 Oct 2026, 12:18 PM	121	4,053.00	LSE
15 Oct 2026, 12:18 PM	43	4,054.00	LSE
15 Oct 2026, 12:18 PM	47	4,054.00	LSE
15 Oct 2026, 12:18 PM	18	4,053.00	LSE
15 Oct 2026, 12:18 PM	22	4,053.00	LSE
15 Oct 2026, 12:21 PM	117	4,049.00	LSE
15 Oct 2026, 12:21 PM	19	4,048.00	LSE
15 Oct 2026, 12:21 PM	100	4,048.00	LSE
15 Oct 2026, 12:23 PM	122	4,054.00	LSE
15 Oct 2026, 12:26 PM	123	4,058.00	LSE
15 Oct 2026, 12:26 PM	111	4,058.00	LSE
15 Oct 2026, 12:51 PM	116	4,050.00	LSE
15 Oct 2026, 01:02 PM	78	4,050.00	LSE
15 Oct 2026, 01:02 PM	34	4,050.00	LSE
15 Oct 2026, 01:10 PM	15	4,050.00	LSE
15 Oct 2026, 01:13 PM	7	4,050.00	LSE
15 Oct 2026, 01:30 PM	121	4,040.00	LSE
15 Oct 2026, 02:31 PM	13	4,040.00	LSE
15 Oct 2026, 02:31 PM	59	4,040.00	LSE
15 Oct 2026, 02:31 PM	53	4,040.00	LSE
15 Oct 2026, 02:31 PM	76	4,038.00	LSE
15 Oct 2026, 02:32 PM	120	4,039.00	LSE
15 Oct 2026, 02:33 PM	121	4,040.00	LSE
15 Oct 2026, 02:33 PM	117	4,039.00	LSE
15 Oct 2026, 02:33 PM	16	4,039.00	LSE
15 Oct 2026, 02:33 PM	117	4,040.00	LSE
15 Oct 2026, 02:34 PM	119	4,039.00	LSE
15 Oct 2026, 02:44 PM	69	4,030.00	LSE
15 Oct 2026, 02:44 PM	139	4,029.00	LSE
15 Oct 2026, 02:44 PM	133	4,028.00	LSE
15 Oct 2026, 02:45 PM	25	4,018.00	LSE
15 Oct 2026, 02:45 PM	102	4,018.00	LSE
15 Oct 2026, 02:46 PM	110	4,018.00	LSE
15 Oct 2026, 02:46 PM	21	4,018.00	LSE
15 Oct 2026, 02:46 PM	121	4,017.00	LSE
15 Oct 2026, 02:47 PM	124	4,028.00	LSE
15 Oct 2026, 02:49 PM	118	4,030.00	LSE
15 Oct 2026, 02:49 PM	20	4,030.00	LSE
15 Oct 2026, 02:49 PM	96	4,030.00	LSE
15 Oct 2026, 02:49 PM	113	4,030.00	LSE
15 Oct 2026, 02:49 PM	139	4,030.00	LSE
15 Oct 2026, 02:50 PM	111	4,028.00	LSE
15 Oct 2026, 02:50 PM	132	4,025.00	LSE
15 Oct 2026, 02:50 PM	38	4,024.00	LSE
15 Oct 2026, 02:50 PM	77	4,024.00	LSE
15 Oct 2026, 02:50 PM	40	4,024.00	LSE
15 Oct 2026, 02:51 PM	134	4,023.00	LSE
15 Oct 2026, 02:53 PM	95	4,024.00	LSE
15 Oct 2026, 02:53 PM	42	4,024.00	LSE
15 Oct 2026, 02:53 PM	62	4,023.00	LSE
15 Oct 2026, 02:53 PM	59	4,023.00	LSE
15 Oct 2026, 02:53 PM	40	4,021.00	LSE
15 Oct 2026, 02:53 PM	137	4,023.00	LSE
15 Oct 2026, 02:54 PM	69	4,025.00	LSE
15 Oct 2026, 02:54 PM	65	4,025.00	LSE
15 Oct 2026, 02:54 PM	158	4,024.00	LSE
15 Oct 2026, 02:54 PM	95	4,023.00	LSE
15 Oct 2026, 02:54 PM	17	4,023.00	LSE
15 Oct 2026, 02:54 PM	124	4,021.00	LSE
15 Oct 2026, 02:55 PM	111	4,024.00	LSE
15 Oct 2026, 02:56 PM	129	4,025.00	LSE
16 Oct 2026, 08:02 AM	22	4,146.00	LSE
16 Oct 2026, 08:02 AM	101	4,146.00	LSE
16 Oct 2026, 08:07 AM	116	4,138.00	LSE
16 Oct 2026, 08:07 AM	127	4,139.00	LSE
16 Oct 2026, 08:09 AM	112	4,128.00	LSE
16 Oct 2026, 08:10 AM	117	4,125.00	LSE
16 Oct 2026, 08:15 AM	186	4,137.00	LSE
16 Oct 2026, 08:15 AM	129	4,133.00	LSE
16 Oct 2026, 08:15 AM	120	4,144.00	LSE
16 Oct 2026, 08:16 AM	112	4,146.00	LSE
16 Oct 2026, 08:16 AM	115	4,141.00	LSE
16 Oct 2026, 08:17 AM	116	4,144.00	LSE
16 Oct 2026, 08:19 AM	130	4,141.00	LSE
16 Oct 2026, 08:19 AM	109	4,140.00	LSE
16 Oct 2026, 08:19 AM	107	4,138.00	LSE
16 Oct 2026, 08:21 AM	21	4,132.00	LSE
16 Oct 2026, 08:21 AM	105	4,132.00	LSE
16 Oct 2026, 08:21 AM	54	4,131.00	LSE
16 Oct 2026, 08:21 AM	73	4,131.00	LSE
16 Oct 2026, 08:23 AM	129	4,129.00	LSE
16 Oct 2026, 08:25 AM	129	4,131.00	LSE
16 Oct 2026, 08:29 AM	42	4,122.00	LSE
16 Oct 2026, 08:29 AM	66	4,122.00	LSE
16 Oct 2026, 08:29 AM	115	4,123.00	LSE
16 Oct 2026, 08:30 AM	11	4,125.00	LSE
16 Oct 2026, 08:30 AM	1	4,125.00	LSE
16 Oct 2026, 08:30 AM	13	4,125.00	LSE
16 Oct 2026, 08:30 AM	92	4,125.00	LSE
16 Oct 2026, 08:30 AM	1	4,125.00	LSE
16 Oct 2026, 08:32 AM	4	4,126.00	LSE
16 Oct 2026, 08:32 AM	8	4,126.00	LSE
16 Oct 2026, 08:32 AM	16	4,126.00	LSE
16 Oct 2026, 08:32 AM	16	4,126.00	LSE
16 Oct 2026, 08:32 AM	8	4,126.00	LSE
16 Oct 2026, 08:33 AM	130	4,128.00	LSE
16 Oct 2026, 08:37 AM	17	4,126.00	LSE
16 Oct 2026, 08:37 AM	101	4,126.00	LSE
16 Oct 2026, 08:40 AM	1	4,121.00	LSE
16 Oct 2026, 08:41 AM	78	4,121.00	LSE
16 Oct 2026, 08:41 AM	18	4,121.00	LSE
16 Oct 2026, 08:41 AM	6	4,121.00	LSE
16 Oct 2026, 08:41 AM	18	4,121.00	LSE
16 Oct 2026, 08:41 AM	6	4,121.00	LSE
16 Oct 2026, 08:43 AM	126	4,130.00	LSE
16 Oct 2026, 08:45 AM	107	4,114.00	LSE
16 Oct 2026, 08:46 AM	38	4,112.00	LSE
16 Oct 2026, 08:46 AM	5	4,112.00	LSE
16 Oct 2026, 08:46 AM	24	4,112.00	LSE
16 Oct 2026, 08:46 AM	24	4,112.00	LSE
16 Oct 2026, 08:47 AM	115	4,110.00	LSE
16 Oct 2026, 08:49 AM	121	4,118.00	LSE
16 Oct 2026, 08:51 AM	116	4,116.00	LSE
16 Oct 2026, 08:52 AM	126	4,123.00	LSE
16 Oct 2026, 08:53 AM	120	4,121.00	LSE
16 Oct 2026, 08:58 AM	124	4,131.00	LSE
16 Oct 2026, 09:01 AM	35	4,127.00	LSE
16 Oct 2026, 09:01 AM	106	4,128.00	LSE
16 Oct 2026, 09:04 AM	128	4,135.00	LSE
16 Oct 2026, 09:08 AM	108	4,137.00	LSE
16 Oct 2026, 09:09 AM	127	4,137.00	LSE
16 Oct 2026, 09:13 AM	129	4,134.00	LSE
16 Oct 2026, 09:14 AM	122	4,138.00	LSE
16 Oct 2026, 09:15 AM	116	4,138.00	LSE
16 Oct 2026, 09:18 AM	81	4,128.00	LSE
16 Oct 2026, 09:18 AM	2	4,128.00	LSE
16 Oct 2026, 09:18 AM	24	4,128.00	LSE
16 Oct 2026, 09:24 AM	3	4,147.00	LSE
16 Oct 2026, 09:24 AM	116	4,147.00	LSE
16 Oct 2026, 09:24 AM	2	4,146.00	LSE
16 Oct 2026, 09:24 AM	24	4,146.00	LSE
16 Oct 2026, 09:26 AM	124	4,149.00	LSE
16 Oct 2026, 09:27 AM	115	4,148.00	LSE
16 Oct 2026, 09:32 AM	130	4,155.00	LSE
16 Oct 2026, 09:32 AM	115	4,152.00	LSE
16 Oct 2026, 09:32 AM	109	4,150.00	LSE
16 Oct 2026, 09:41 AM	126	4,159.00	LSE
16 Oct 2026, 09:44 AM	132	4,161.00	LSE
16 Oct 2026, 09:45 AM	132	4,165.00	LSE
16 Oct 2026, 09:45 AM	122	4,164.00	LSE
16 Oct 2026, 09:46 AM	112	4,165.00	LSE
16 Oct 2026, 09:47 AM	123	4,159.00	LSE
16 Oct 2026, 09:52 AM	128	4,155.00	LSE
16 Oct 2026, 09:53 AM	107	4,155.00	LSE
16 Oct 2026, 09:54 AM	6	4,153.00	LSE
16 Oct 2026, 09:54 AM	129	4,153.00	LSE
16 Oct 2026, 09:55 AM	131	4,158.00	LSE
16 Oct 2026, 09:55 AM	24	4,156.00	LSE
16 Oct 2026, 09:57 AM	3	4,156.00	LSE
16 Oct 2026, 09:57 AM	21	4,156.00	LSE
16 Oct 2026, 09:58 AM	103	4,156.00	LSE
16 Oct 2026, 09:59 AM	123	4,154.00	LSE
16 Oct 2026, 10:00 AM	125	4,149.00	LSE
16 Oct 2026, 10:03 AM	107	4,151.00	LSE
16 Oct 2026, 10:04 AM	122	4,152.00	LSE
16 Oct 2026, 10:07 AM	87	4,159.00	LSE
16 Oct 2026, 10:09 AM	19	4,159.00	LSE
16 Oct 2026, 10:15 AM	467	4,166.00	LSE
16 Oct 2026, 10:15 AM	13	4,168.00	LSE
16 Oct 2026, 10:15 AM	217	4,168.00	LSE
16 Oct 2026, 10:15 AM	110	4,165.00	LSE
16 Oct 2026, 10:15 AM	114	4,164.00	LSE
16 Oct 2026, 10:16 AM	10	4,160.00	LSE
16 Oct 2026, 10:16 AM	24	4,160.00	LSE
16 Oct 2026, 10:16 AM	24	4,160.00	LSE
16 Oct 2026, 10:16 AM	126	4,160.00	LSE
16 Oct 2026, 10:18 AM	122	4,158.00	LSE
16 Oct 2026, 10:18 AM	112	4,155.00	LSE
16 Oct 2026, 10:22 AM	114	4,152.00	LSE
16 Oct 2026, 10:23 AM	115	4,152.00	LSE
16 Oct 2026, 10:23 AM	21	4,153.00	LSE
16 Oct 2026, 10:23 AM	89	4,153.00	LSE
16 Oct 2026, 10:26 AM	124	4,152.00	LSE
16 Oct 2026, 10:27 AM	122	4,152.00	LSE
16 Oct 2026, 10:29 AM	42	4,152.00	LSE
16 Oct 2026, 10:29 AM	67	4,152.00	LSE
16 Oct 2026, 10:31 AM	108	4,146.00	LSE
16 Oct 2026, 10:34 AM	125	4,147.00	LSE
16 Oct 2026, 10:34 AM	115	4,147.00	LSE
16 Oct 2026, 10:38 AM	110	4,151.00	LSE
16 Oct 2026, 10:45 AM	115	4,144.00	LSE
16 Oct 2026, 10:47 AM	110	4,150.00	LSE
16 Oct 2026, 10:50 AM	39	4,152.00	LSE
16 Oct 2026, 10:52 AM	42	4,155.00	LSE
16 Oct 2026, 10:52 AM	80	4,155.00	LSE
16 Oct 2026, 11:02 AM	113	4,151.00	LSE
16 Oct 2026, 11:02 AM	16	4,150.00	LSE
16 Oct 2026, 11:06 AM	118	4,150.00	LSE
16 Oct 2026, 11:09 AM	118	4,155.00	LSE
16 Oct 2026, 11:09 AM	182	4,158.00	LSE
16 Oct 2026, 11:09 AM	129	4,159.00	LSE
16 Oct 2026, 11:15 AM	29	4,165.00	LSE
16 Oct 2026, 11:15 AM	107	4,164.00	LSE
16 Oct 2026, 11:25 AM	1	4,168.00	LSE
16 Oct 2026, 11:25 AM	24	4,168.00	LSE
16 Oct 2026, 11:25 AM	132	4,170.00	LSE
16 Oct 2026, 11:32 AM	131	4,170.00	LSE
16 Oct 2026, 11:35 AM	116	4,169.00	LSE
16 Oct 2026, 11:40 AM	127	4,168.00	LSE
16 Oct 2026, 11:43 AM	130	4,161.00	LSE
16 Oct 2026, 11:45 AM	127	4,164.00	LSE
16 Oct 2026, 11:50 AM	120	4,160.00	LSE
16 Oct 2026, 11:52 AM	124	4,159.00	LSE
16 Oct 2026, 11:53 AM	106	4,163.00	LSE
16 Oct 2026, 11:54 AM	28	4,156.00	LSE
16 Oct 2026, 11:54 AM	44	4,156.00	LSE
16 Oct 2026, 11:54 AM	15	4,157.00	LSE
16 Oct 2026, 11:54 AM	46	4,156.00	LSE
16 Oct 2026, 11:54 AM	39	4,156.00	LSE
16 Oct 2026, 11:54 AM	82	4,152.00	LSE
16 Oct 2026, 11:54 AM	50	4,152.00	LSE
16 Oct 2026, 12:00 PM	163	4,151.00	LSE
16 Oct 2026, 12:00 PM	125	4,149.00	LSE
16 Oct 2026, 12:00 PM	106	4,148.00	LSE
16 Oct 2026, 12:01 PM	76	4,147.00	LSE
16 Oct 2026, 12:01 PM	110	4,146.00	LSE
16 Oct 2026, 12:07 PM	108	4,141.00	LSE
16 Oct 2026, 12:07 PM	28	4,142.00	LSE
16 Oct 2026, 12:07 PM	80	4,142.00	LSE
16 Oct 2026, 12:09 PM	6	4,140.00	LSE
16 Oct 2026, 12:09 PM	123	4,140.00	LSE
16 Oct 2026, 12:14 PM	126	4,140.00	LSE
16 Oct 2026, 12:19 PM	127	4,145.00	LSE
16 Oct 2026, 12:20 PM	33	4,143.00	LSE
16 Oct 2026, 12:20 PM	125	4,141.00	LSE
16 Oct 2026, 12:24 PM	24	4,139.00	LSE
16 Oct 2026, 12:25 PM	114	4,140.00	LSE
16 Oct 2026, 12:30 PM	120	4,138.00	LSE
16 Oct 2026, 12:31 PM	32	4,136.00	LSE
16 Oct 2026, 12:31 PM	93	4,136.00	LSE
16 Oct 2026, 12:33 PM	108	4,134.00	LSE
16 Oct 2026, 12:36 PM	14	4,137.00	LSE
16 Oct 2026, 12:36 PM	107	4,137.00	LSE
16 Oct 2026, 12:40 PM	28	4,138.00	LSE
16 Oct 2026, 12:40 PM	103	4,138.00	LSE
16 Oct 2026, 12:42 PM	120	4,139.00	LSE
16 Oct 2026, 12:45 PM	127	4,138.00	LSE
16 Oct 2026, 12:50 PM	120	4,135.00	LSE
16 Oct 2026, 12:53 PM	95	4,131.00	LSE
16 Oct 2026, 12:53 PM	23	4,131.00	LSE
16 Oct 2026, 12:53 PM	1	4,131.00	LSE
16 Oct 2026, 12:56 PM	9	4,129.00	LSE
16 Oct 2026, 12:56 PM	24	4,129.00	LSE
16 Oct 2026, 12:57 PM	108	4,128.00	LSE
16 Oct 2026, 12:57 PM	35	4,128.00	LSE
16 Oct 2026, 01:03 PM	129	4,118.00	LSE
16 Oct 2026, 01:04 PM	128	4,119.00	LSE
16 Oct 2026, 01:08 PM	2	4,125.00	LSE
16 Oct 2026, 01:08 PM	24	4,125.00	LSE
16 Oct 2026, 01:08 PM	125	4,123.00	LSE
16 Oct 2026, 01:11 PM	121	4,127.00	LSE
16 Oct 2026, 01:12 PM	2	4,126.00	LSE
16 Oct 2026, 01:12 PM	24	4,126.00	LSE
16 Oct 2026, 01:12 PM	128	4,122.00	LSE
16 Oct 2026, 01:14 PM	125	4,122.00	LSE
16 Oct 2026, 01:25 PM	122	4,134.00	LSE
16 Oct 2026, 01:25 PM	24	4,132.00	LSE
16 Oct 2026, 01:29 PM	115	4,130.00	LSE
16 Oct 2026, 01:31 PM	116	4,133.00	LSE
16 Oct 2026, 01:32 PM	109	4,134.00	LSE
16 Oct 2026, 01:37 PM	21	4,140.00	LSE
16 Oct 2026, 01:37 PM	90	4,140.00	LSE
16 Oct 2026, 01:42 PM	91	4,137.00	LSE
16 Oct 2026, 01:42 PM	1	4,137.00	LSE
16 Oct 2026, 01:45 PM	2	4,135.00	LSE
16 Oct 2026, 01:45 PM	24	4,135.00	LSE
16 Oct 2026, 01:47 PM	15	4,138.00	LSE
16 Oct 2026, 01:47 PM	116	4,138.00	LSE
16 Oct 2026, 01:47 PM	106	4,137.00	LSE
16 Oct 2026, 01:53 PM	108	4,134.00	LSE
16 Oct 2026, 01:53 PM	67	4,133.00	LSE
16 Oct 2026, 01:53 PM	49	4,133.00	LSE
16 Oct 2026, 01:54 PM	119	4,134.00	LSE
16 Oct 2026, 01:54 PM	110	4,135.00	LSE
16 Oct 2026, 01:54 PM	13	4,135.00	LSE
16 Oct 2026, 01:55 PM	119	4,134.00	LSE
16 Oct 2026, 01:55 PM	3	4,134.00	LSE
16 Oct 2026, 01:57 PM	111	4,129.00	LSE
16 Oct 2026, 01:58 PM	109	4,126.00	LSE
16 Oct 2026, 01:58 PM	22	4,126.00	LSE
16 Oct 2026, 02:00 PM	131	4,134.00	LSE
16 Oct 2026, 02:00 PM	20	4,143.00	LSE
16 Oct 2026, 02:00 PM	90	4,143.00	LSE
16 Oct 2026, 02:01 PM	113	4,143.00	LSE
16 Oct 2026, 02:07 PM	112	4,149.00	LSE
16 Oct 2026, 02:09 PM	132	4,143.00	LSE
16 Oct 2026, 02:15 PM	64	4,137.00	LSE
16 Oct 2026, 02:15 PM	55	4,137.00	LSE
16 Oct 2026, 02:17 PM	94	4,129.00	LSE
16 Oct 2026, 02:17 PM	4	4,129.00	LSE
16 Oct 2026, 02:17 PM	20	4,129.00	LSE
16 Oct 2026, 02:18 PM	118	4,129.00	LSE
16 Oct 2026, 02:21 PM	65	4,128.00	LSE
16 Oct 2026, 02:21 PM	52	4,128.00	LSE
16 Oct 2026, 02:23 PM	115	4,125.00	LSE
16 Oct 2026, 02:26 PM	111	4,125.00	LSE
16 Oct 2026, 02:26 PM	12	4,125.00	LSE
16 Oct 2026, 02:28 PM	44	4,131.00	LSE
16 Oct 2026, 02:28 PM	122	4,131.00	LSE
16 Oct 2026, 02:29 PM	44	4,139.00	LSE
16 Oct 2026, 02:29 PM	125	4,139.00	LSE
16 Oct 2026, 02:29 PM	98	4,139.00	LSE
16 Oct 2026, 02:31 PM	108	4,146.00	LSE
16 Oct 2026, 02:31 PM	124	4,145.00	LSE
16 Oct 2026, 02:31 PM	119	4,146.00	LSE
16 Oct 2026, 02:31 PM	107	4,144.00	LSE
16 Oct 2026, 02:31 PM	21	4,144.00	LSE
16 Oct 2026, 02:31 PM	116	4,142.00	LSE
16 Oct 2026, 02:32 PM	85	4,136.00	LSE
16 Oct 2026, 02:32 PM	37	4,136.00	LSE
16 Oct 2026, 02:32 PM	8	4,136.00	LSE
16 Oct 2026, 02:32 PM	100	4,127.00	LSE
16 Oct 2026, 02:32 PM	22	4,127.00	LSE
16 Oct 2026, 02:32 PM	132	4,130.00	LSE
16 Oct 2026, 02:32 PM	251	4,132.00	LSE
16 Oct 2026, 02:32 PM	64	4,130.00	LSE
16 Oct 2026, 02:32 PM	53	4,130.00	LSE
16 Oct 2026, 02:32 PM	48	4,131.00	LSE
16 Oct 2026, 02:32 PM	72	4,131.00	LSE
16 Oct 2026, 02:32 PM	6	4,136.00	LSE
16 Oct 2026, 02:32 PM	71	4,136.00	LSE
16 Oct 2026, 02:32 PM	56	4,136.00	LSE
16 Oct 2026, 02:33 PM	130	4,136.00	LSE
16 Oct 2026, 02:33 PM	127	4,146.00	LSE
16 Oct 2026, 02:54 PM	58	4,187.00	LSE
16 Oct 2026, 02:54 PM	62	4,187.00	LSE
16 Oct 2026, 02:54 PM	110	4,187.00	LSE
16 Oct 2026, 02:54 PM	37	4,187.00	LSE
16 Oct 2026, 02:54 PM	69	4,187.00	LSE
16 Oct 2026, 02:54 PM	37	4,187.00	LSE
16 Oct 2026, 02:55 PM	126	4,184.00	LSE
16 Oct 2026, 02:56 PM	122	4,183.00	LSE
16 Oct 2026, 02:56 PM	10	4,187.00	LSE
16 Oct 2026, 02:56 PM	103	4,187.00	LSE
16 Oct 2026, 02:56 PM	4	4,187.00	LSE
16 Oct 2026, 02:56 PM	21	4,186.00	LSE
16 Oct 2026, 02:56 PM	88	4,186.00	LSE
16 Oct 2026, 02:57 PM	88	4,187.00	LSE
16 Oct 2026, 02:57 PM	44	4,187.00	LSE
16 Oct 2026, 02:57 PM	37	4,183.00	LSE
16 Oct 2026, 02:57 PM	83	4,183.00	LSE
16 Oct 2026, 02:58 PM	103	4,187.00	LSE
16 Oct 2026, 02:58 PM	72	4,183.00	LSE
16 Oct 2026, 02:58 PM	53	4,183.00	LSE
16 Oct 2026, 02:59 PM	94	4,183.00	LSE
16 Oct 2026, 02:59 PM	128	4,181.00	LSE
16 Oct 2026, 03:00 PM	127	4,179.00	LSE
16 Oct 2026, 03:00 PM	120	4,189.00	LSE
16 Oct 2026, 03:00 PM	1	4,182.00	LSE
16 Oct 2026, 03:00 PM	144	4,182.00	LSE
16 Oct 2026, 03:00 PM	12	4,182.00	LSE
16 Oct 2026, 03:00 PM	104	4,182.00	LSE
16 Oct 2026, 03:00 PM	94	4,188.00	LSE
16 Oct 2026, 03:00 PM	95	4,189.00	LSE
16 Oct 2026, 03:01 PM	75	4,190.00	LSE
16 Oct 2026, 03:01 PM	40	4,190.00	LSE
16 Oct 2026, 03:01 PM	132	4,184.00	LSE
16 Oct 2026, 03:01 PM	19	4,184.00	LSE
16 Oct 2026, 03:01 PM	112	4,184.00	LSE
16 Oct 2026, 03:02 PM	122	4,188.00	LSE
16 Oct 2026, 03:02 PM	72	4,181.00	LSE
16 Oct 2026, 03:02 PM	58	4,181.00	LSE
16 Oct 2026, 03:02 PM	122	4,185.00	LSE
16 Oct 2026, 03:03 PM	111	4,180.00	LSE
16 Oct 2026, 03:03 PM	31	4,180.00	LSE
16 Oct 2026, 03:03 PM	89	4,180.00	LSE
16 Oct 2026, 03:03 PM	3	4,180.00	LSE
16 Oct 2026, 03:03 PM	33	4,180.00	LSE
16 Oct 2026, 03:03 PM	90	4,180.00	LSE
16 Oct 2026, 03:04 PM	108	4,177.00	LSE
16 Oct 2026, 03:04 PM	118	4,169.00	LSE
16 Oct 2026, 03:04 PM	1	4,169.00	LSE
16 Oct 2026, 03:06 PM	117	4,169.00	LSE
16 Oct 2026, 03:07 PM	128	4,172.00	LSE
16 Oct 2026, 03:07 PM	2	4,172.00	LSE
16 Oct 2026, 03:07 PM	24	4,172.00	LSE
16 Oct 2026, 03:07 PM	36	4,172.00	LSE
16 Oct 2026, 03:07 PM	18	4,180.00	LSE
16 Oct 2026, 03:07 PM	115	4,179.00	LSE
16 Oct 2026, 03:08 PM	107	4,182.00	LSE
16 Oct 2026, 03:10 PM	113	4,189.00	LSE
16 Oct 2026, 03:11 PM	107	4,190.00	LSE
16 Oct 2026, 03:12 PM	96	4,190.00	LSE
16 Oct 2026, 03:12 PM	36	4,190.00	LSE
16 Oct 2026, 03:14 PM	119	4,188.00	LSE
16 Oct 2026, 03:14 PM	44	4,188.00	LSE
16 Oct 2026, 03:14 PM	79	4,188.00	LSE
16 Oct 2026, 03:30 PM	50	4,215.00	LSE
16 Oct 2026, 03:30 PM	79	4,215.00	LSE
16 Oct 2026, 03:31 PM	112	4,218.00	LSE
16 Oct 2026, 03:32 PM	122	4,220.00	LSE
16 Oct 2026, 03:33 PM	27	4,215.00	LSE
16 Oct 2026, 03:33 PM	55	4,215.00	LSE
16 Oct 2026, 03:33 PM	3	4,215.00	LSE
16 Oct 2026, 03:33 PM	117	4,216.00	LSE
16 Oct 2026, 03:35 PM	123	4,210.00	LSE
16 Oct 2026, 03:35 PM	37	4,207.00	LSE
16 Oct 2026, 03:35 PM	89	4,207.00	LSE
16 Oct 2026, 03:35 PM	10	4,209.00	LSE
16 Oct 2026, 03:35 PM	103	4,209.00	LSE
16 Oct 2026, 03:35 PM	135	4,210.00	LSE
16 Oct 2026, 03:36 PM	88	4,209.00	LSE
16 Oct 2026, 03:36 PM	116	4,207.00	LSE
16 Oct 2026, 03:36 PM	73	4,204.00	LSE
16 Oct 2026, 03:36 PM	56	4,204.00	LSE
16 Oct 2026, 03:37 PM	127	4,202.00	LSE
16 Oct 2026, 03:37 PM	106	4,202.00	LSE
16 Oct 2026, 03:38 PM	126	4,204.00	LSE
16 Oct 2026, 03:38 PM	109	4,203.00	LSE
16 Oct 2026, 03:39 PM	107	4,199.00	LSE
16 Oct 2026, 03:41 PM	14	4,200.00	LSE
16 Oct 2026, 03:41 PM	79	4,200.00	LSE
16 Oct 2026, 03:41 PM	18	4,200.00	LSE
16 Oct 2026, 03:42 PM	103	4,209.00	LSE
16 Oct 2026, 03:42 PM	14	4,209.00	LSE
16 Oct 2026, 03:43 PM	119	4,205.00	LSE
16 Oct 2026, 03:45 PM	119	4,201.00	LSE
16 Oct 2026, 03:46 PM	126	4,203.00	LSE
16 Oct 2026, 03:47 PM	24	4,206.00	LSE
16 Oct 2026, 03:48 PM	117	4,207.00	LSE
16 Oct 2026, 03:49 PM	108	4,206.00	LSE
16 Oct 2026, 03:51 PM	129	4,213.00	LSE
16 Oct 2026, 03:51 PM	5	4,218.00	LSE
16 Oct 2026, 03:51 PM	128	4,216.00	LSE
16 Oct 2026, 03:53 PM	126	4,215.00	LSE
16 Oct 2026, 03:55 PM	111	4,220.00	LSE
16 Oct 2026, 03:56 PM	44	4,216.00	LSE
16 Oct 2026, 03:56 PM	80	4,216.00	LSE
16 Oct 2026, 03:58 PM	33	4,214.00	LSE
16 Oct 2026, 03:58 PM	80	4,214.00	LSE
16 Oct 2026, 03:58 PM	66	4,215.00	LSE
16 Oct 2026, 03:58 PM	70	4,215.00	LSE
16 Oct 2026, 03:58 PM	35	4,214.00	LSE
16 Oct 2026, 03:58 PM	80	4,214.00	LSE
16 Oct 2026, 03:58 PM	108	4,212.00	LSE
16 Oct 2026, 04:00 PM	115	4,211.00	LSE
16 Oct 2026, 04:01 PM	34	4,208.00	LSE
16 Oct 2026, 04:01 PM	80	4,208.00	LSE
16 Oct 2026, 04:01 PM	106	4,207.00	LSE
16 Oct 2026, 04:03 PM	113	4,211.00	LSE
16 Oct 2026, 04:04 PM	122	4,212.00	LSE
16 Oct 2026, 04:06 PM	87	4,212.00	LSE
16 Oct 2026, 04:06 PM	43	4,212.00	LSE
16 Oct 2026, 04:06 PM	92	4,210.00	LSE
16 Oct 2026, 04:06 PM	27	4,210.00	LSE
16 Oct 2026, 04:07 PM	109	4,209.00	LSE
16 Oct 2026, 04:07 PM	12	4,209.00	LSE
16 Oct 2026, 04:07 PM	119	4,209.00	LSE
16 Oct 2026, 04:07 PM	59	4,206.00	LSE
16 Oct 2026, 04:08 PM	90	4,207.00	LSE
16 Oct 2026, 04:08 PM	28	4,207.00	LSE
16 Oct 2026, 04:10 PM	108	4,208.00	LSE
16 Oct 2026, 04:10 PM	112	4,206.00	LSE
16 Oct 2026, 04:11 PM	76	4,202.00	LSE
16 Oct 2026, 04:11 PM	48	4,202.00	LSE
16 Oct 2026, 04:13 PM	124	4,205.00	LSE
16 Oct 2026, 04:13 PM	80	4,203.00	LSE
16 Oct 2026, 04:13 PM	43	4,204.00	LSE
16 Oct 2026, 04:14 PM	80	4,203.00	LSE
16 Oct 2026, 04:14 PM	121	4,202.00	LSE
16 Oct 2026, 04:14 PM	107	4,199.00	LSE
16 Oct 2026, 04:14 PM	22	4,199.00	LSE
16 Oct 2026, 04:14 PM	29	4,199.00	LSE
16 Oct 2026, 04:14 PM	93	4,199.00	LSE
16 Oct 2026, 04:14 PM	1	4,199.00	LSE
16 Oct 2026, 04:15 PM	84	4,196.00	LSE
16 Oct 2026, 04:15 PM	108	4,198.00	LSE
16 Oct 2026, 04:15 PM	19	4,196.00	LSE
16 Oct 2026, 04:16 PM	80	4,200.00	LSE
16 Oct 2026, 04:17 PM	123	4,197.00	LSE
16 Oct 2026, 04:17 PM	115	4,197.00	LSE
16 Oct 2026, 04:17 PM	7	4,197.00	LSE
16 Oct 2026, 04:17 PM	107	4,196.00	LSE
16 Oct 2026, 04:17 PM	440	4,203.00	LSE
16 Oct 2026, 04:17 PM	104	4,203.00	LSE
16 Oct 2026, 04:17 PM	67	4,203.00	LSE
16 Oct 2026, 04:17 PM	80	4,203.00	LSE
16 Oct 2026, 04:17 PM	35	4,203.00	LSE
16 Oct 2026, 04:17 PM	80	4,203.00	LSE
16 Oct 2026, 04:17 PM	126	4,203.00	LSE
16 Oct 2026, 04:17 PM	80	4,206.00	LSE
16 Oct 2026, 04:17 PM	113	4,206.00	LSE
16 Oct 2026, 04:18 PM	48	4,208.00	LSE
16 Oct 2026, 04:18 PM	129	4,210.00	LSE
16 Oct 2026, 04:18 PM	112	4,210.00	LSE
16 Oct 2026, 04:18 PM	20	4,210.00	LSE
16 Oct 2026, 04:18 PM	80	4,210.00	LSE
16 Oct 2026, 04:18 PM	80	4,207.00	LSE
16 Oct 2026, 04:18 PM	21	4,207.00	LSE
16 Oct 2026, 04:19 PM	109	4,207.00	LSE
16 Oct 2026, 04:19 PM	2	4,206.00	LSE
16 Oct 2026, 04:20 PM	126	4,205.00	LSE
16 Oct 2026, 04:20 PM	59	4,204.00	LSE
16 Oct 2026, 04:20 PM	56	4,204.00	LSE
16 Oct 2026, 04:20 PM	44	4,208.00	LSE
16 Oct 2026, 04:20 PM	80	4,208.00	LSE
16 Oct 2026, 04:21 PM	119	4,204.00	LSE
16 Oct 2026, 04:22 PM	1	4,199.00	LSE
16 Oct 2026, 04:22 PM	115	4,199.00	LSE
16 Oct 2026, 04:22 PM	132	4,196.00	LSE
16 Oct 2026, 04:22 PM	59	4,195.00	LSE
16 Oct 2026, 04:23 PM	88	4,196.00	LSE
16 Oct 2026, 04:23 PM	114	4,195.00	LSE
16 Oct 2026, 04:24 PM	88	4,191.00	LSE
16 Oct 2026, 04:24 PM	66	4,191.00	LSE
16 Oct 2026, 04:24 PM	132	4,191.00	LSE
16 Oct 2026, 04:24 PM	38	4,189.00	LSE
16 Oct 2026, 04:24 PM	79	4,189.00	LSE
16 Oct 2026, 04:24 PM	88	4,189.00	LSE
16 Oct 2026, 04:25 PM	110	4,196.00	LSE
16 Oct 2026, 04:25 PM	1	4,197.00	LSE
16 Oct 2026, 04:25 PM	123	4,200.00	LSE
16 Oct 2026, 04:25 PM	2	4,200.00	LSE
16 Oct 2026, 04:25 PM	119	4,199.00	LSE
16 Oct 2026, 04:25 PM	114	4,199.00	LSE
16 Oct 2026, 04:25 PM	126	4,198.00	LSE
16 Oct 2026, 04:25 PM	23	4,198.00	LSE
16 Oct 2026, 04:25 PM	35	4,197.00	LSE
16 Oct 2026, 04:25 PM	88	4,197.00	LSE
16 Oct 2026, 04:25 PM	117	4,195.00	LSE
16 Oct 2026, 04:25 PM	88	4,194.00	LSE
16 Oct 2026, 04:25 PM	128	4,188.00	LSE
16 Oct 2026, 04:25 PM	118	4,187.00	LSE
16 Oct 2026, 04:25 PM	129	4,187.00	LSE
16 Oct 2026, 04:25 PM	37	4,188.00	LSE
16 Oct 2026, 04:25 PM	35	4,189.00	LSE
16 Oct 2026, 04:25 PM	83	4,189.00	LSE
16 Oct 2026, 04:25 PM	18	4,189.00	LSE
16 Oct 2026, 04:26 PM	86	4,190.00	LSE
16 Oct 2026, 04:26 PM	66	4,190.00	LSE
16 Oct 2026, 04:26 PM	35	4,188.00	LSE
16 Oct 2026, 04:26 PM	83	4,188.00	LSE
16 Oct 2026, 04:26 PM	12	4,188.00	LSE
16 Oct 2026, 04:26 PM	75	4,188.00	LSE
16 Oct 2026, 04:27 PM	25	4,193.00	LSE
16 Oct 2026, 04:27 PM	88	4,193.00	LSE
16 Oct 2026, 04:27 PM	44	4,193.00	LSE
16 Oct 2026, 04:27 PM	88	4,193.00	LSE
16 Oct 2026, 04:27 PM	24	4,194.00	LSE
16 Oct 2026, 04:27 PM	88	4,194.00	LSE
16 Oct 2026, 04:28 PM	129	4,194.00	LSE
16 Oct 2026, 04:28 PM	87	4,192.00	LSE
16 Oct 2026, 04:28 PM	29	4,192.00	LSE
16 Oct 2026, 04:28 PM	55	4,192.00	LSE
16 Oct 2026, 04:29 PM	29	4,194.00	LSE
16 Oct 2026, 04:29 PM	32	4,194.00	LSE
16 Oct 2026, 04:29 PM	88	4,194.00	LSE
16 Oct 2026, 04:29 PM	29	4,194.00	LSE
16 Oct 2026, 04:29 PM	33	4,193.00	LSE
16 Oct 2026, 04:29 PM	115	4,193.00	LSE
16 Oct 2026, 04:29 PM	34	4,189.00	LSE

CONTACT INFORMATION

For Investor Relations Enquiries:	For Media Enquiries:
Jack Garman	Brunswick Group LLP in London
Vice President of Investor Relations	Carole Cable, Partner
+44 203 011 2723	+ 44 207 404 5959
investor@endeavourmining.com	ccable@brunswickgroup.com

ABOUT ENDEAVOUR MINING PLC

Endeavour Mining is one of the world’s senior gold producers and the largest in West Africa, with operating assets across Senegal, Cote d’Ivoire and Burkina Faso and a strong portfolio of advanced development projects and exploration assets.

A member of the World Gold Council, Endeavour is committed to the principles of responsible mining and delivering sustainable value to its employees, stakeholders and the communities where it operates. Endeavour is admitted to listing and to trading on the London Stock Exchange and the Toronto Stock Exchange, under the symbol EDV.

For more information, please visit www.endeavourmining.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION

This news release contains “forward-looking statements” within the meaning of applicable securities laws.  All statements, other than statements of historical fact, are “forward-looking statements”. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “expects”, “expected”, “budgeted”, “forecasts”, and “anticipates”.

Forward-looking statements, while based on management’s best estimates and assumptions, are subject to risks and uncertainties that may cause actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: risks related to the successful integration of acquisitions; risks related to international operations; risks related to general economic conditions and credit availability, actual results of current exploration activities, unanticipated reclamation expenses; changes in project parameters as plans continue to be refined; fluctuations in prices of metals including gold; fluctuations in foreign currency exchange rates, increases in market prices of mining consumables, possible variations in ore reserves, grade or recovery rates; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes, title disputes, claims and limitations on insurance coverage and other risks of the mining industry; delays in the completion of development or construction activities, changes in national and local government regulation of mining operations, tax rules and regulations, and political and economic developments in countries in which Endeavour operates. Although Endeavour has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Please refer to Endeavour’s most recent Annual Information Form filed under its profile at www.sedarplus.ca for further information respecting the risks affecting Endeavour and its business.

Attachment

• Transaction in own shares

Please see below information about transactions made under the buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR) for shares to be used in the share-based incentive programmes for employees and management.

Date on which the buy-back programme was announced: 4 February 2026.

The duration of the buy-back programme: 13 February 2026 to 15 January 2027.

Size of the buy-back programme: The total purchase amount under the programme is NOK 1,971,000,000 and the maximum shares to be acquired is 19,600,000 shares, of which up to 7,920,000 shares can be acquired in the period from 13 February 2026 to 15 May 2026, and up to 11,680,000 shares can be acquired in the period from 15 May 2026 to 15 January 2027.

On 15 October 2026, Equinor ASA has purchased a total of 389,058 own shares at the Oslo Stock Exchange at an average price of NOK 429.2415 per share.

Aggregated overview of transactions per day:

Date	Aggregated volume (number of shares)	Weighted average share price (NOK)	Total transaction value (NOK)
15 October 2026	389,058	429.2415	166,999,840
Previously disclosed buy-backs under the programme (accumulated)	3,778,442	344.8107	1,302,847,119
Total buy-backs under the programme	4,167,500	352.6927	1,469,846,959

Following the completion of the above transactions, Equinor ASA owns a total of 23,077,317 own shares, corresponding to 0.97% of Equinor ASA’s share capital, including shares purchased under the previous buy-back programme for the share-based incentive programmes for employees, and shares purchased under Equinor’s disclosed buy-back programmes which will be used to reduce the issued share capital of the company.

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: A detailed overview of all transactions made under the buy-back programme that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Further information from

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Attachment

• Equinor Employee share saving programme – 15 October 2026

Press release – Neuilly-sur-Seine, Tuesday, October 19, 2026 – 8.00 am

Availability of the Merger Auditor’s Report

ARGAN hereby informs its shareholders that the report prepared by Mr. Olivier Péronnet, Partner at Finexsi – Expert & Conseil Financier, acting as merger auditor appointed by order of the President of the Nanterre Commercial Activities Court dated July 28, 2026, is available to them as of today.

In his report, prepared in connection with the proposed cross-border merger with Warehouses De Pauw NV (“WDP”), a company incorporated under Belgian law, the merger auditor concludes as follows:

• “The exchange ratio of 3 WDP shares for 1 ARGAN share, following the exceptional distribution of €11 per share, as agreed by the parties, is fair; and
• The withdrawal price of €71.10 agreed upon by the parties, corresponding to €60.10 following the exceptional distribution of €11.00 per share, is based on valuation criteria that we consider appropriate and appears justified in the context of the merger.”

The report is available for consultation in its entirety on the argan.fr website, under the “General Meetings – 2026” section of the “Investors & Shareholders” tab.

This report supplements the documentation prepared in advance of ARGAN’s Combined General Meeting of Shareholders, which will be held on Friday, November 20, 2026, at 11:00 a.m. at the Palais Brongniart (16, place de la Bourse, 75002 Paris), and at which shareholders will be asked, in particular, to vote on the proposed merger.

The proposed merger is progressing in line with the planned timetable, with completion expected in the first quarter of 2027, subject to the satisfaction of the conditions precedent to the transaction, including approval by the shareholders of both companies. Further information on the proposed merger is available on the website www.wdp-argan.eu.

2026 financial calendar

• November 20: Combined General Meeting (WDP merger project)

2027¹ financial calendar (Publication of the press release after closing of the stock exchange)

• January 4: Net sales of 4^th quarter 2026
• January 21: Annual results 2026
• March 25: General Meeting 2027

Disclaimer

The envisaged merger does not constitute an offering in Belgium, France or another state or jurisdiction, other than the United States, where the offering will be made pursuant to the exemption of Rule 802 under the U.S. Securities Act of 1933, as amended (the “Securities Act”). No action has been or will be taken to permit an offering in any state or jurisdiction other than the United States.

This press release may not be construed as a prospectus or an information document as referred to in Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), or any implementing measure in any relevant member state of the European Economic Area.

This press release does not constitute an offer or solicitation to acquire, purchase, subscribe for, sell or exchange any securities in Australia, Hong Kong, Canada, Japan, New Zealand, South Africa, Switzerland and the United Kingdom, or any other state or jurisdiction where to do so would constitute a violation of the laws of that state or jurisdiction, and no such offer (or solicitation) may be made in any such jurisdiction. Any failure to comply with this restriction may constitute a violation of the securities laws of Australia, Hong Kong, Canada, Japan, New Zealand, South Africa, Switzerland and the United Kingdom, or other applicable laws. All people who read this announcement should inform themselves of any such restrictions and comply with them. This announcement is not intended for release, publication, or distribution, in whole or in part, in or into, directly or indirectly, any jurisdiction in which such release, publication, or distribution could constitute a breach of the applicable laws of such jurisdiction. ARGAN and WDP explicitly decline any liability for breach of these restrictions by any person.

The shares to be issued in connection with the envisaged merger may not be offered or sold in the United States except pursuant to an effective registration statement under the Securities Act, or pursuant to a valid exemption from registration. WDP is offering its shares in connection with the envisaged merger in the United States in reliance on the exemption from registration provided by Rule 802 under the Securities Act (“Rule 802”).

Important Notice to U.S. Investors

The merger will involve the exchange of securities of a public limited liability company incorporated in Belgium and a public limited company incorporated in France. The offer of shares in the merger is subject to disclosure requirements of a foreign country that are different from those of the United States. Financial statements included or referred to in this document, if any, have been prepared in accordance with foreign accounting standards that may not be comparable to the financial statements of United States companies. It may be difficult for you to enforce your rights and any claim you may have arising under the U.S. federal securities laws, since WDP is located in a foreign country, and some or all of its officers and directors may be residents of a foreign country. You may not be able to sue a foreign company or its officers or directors in a foreign court for violations of the U.S. securities laws. It may be difficult to compel a foreign company and its affiliates to subject themselves to a U.S. court’s judgment.

You should be aware that WDP may purchase securities otherwise than in the context of the merger, such as in open market or privately negotiated purchases.

About ARGAN

ARGAN is the only French real estate company specializing in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT and is the leading player in its market in France. Building on a unique customer-centric approach, ARGAN develops PREMIUM and pre-let Au0nom® -labelled warehouses – i.e., which produce their own energy for self-consumption – for blue-chip companies, with tailor-made services throughout all project phases from the development milestones to the rental management. As at June 30, 2026, ARGAN represented a portfolio of 3.9 million sq.m, with close to 110 warehouses located in the continental area of France. Appraised at a total of €4.3 billion (excl. duties), this portfolio generates a yearly rental income of €224 million (yearly rental income based on the portfolio delivered as at June 30, 2026).
Profitability, well-mastered debt and sustainability are at the heart of ARGAN’s DNA. The financial solidity of the Group’s model is notably reflected in its Investment-grade rating (BBB- with a stable outlook) with Standard & Poor’s. ARGAN is also deploying a committed ESG policy addressing all its stakeholders. Achievements as part of this roadmap are regularly recognized by third-party agencies such as GRESB (rated: 83/100), Sustainalytics (low extra-financial risk), Ethifinance (gold medal) and Ecovadis (silver medal – top 15% amongst rated companies).
ARGAN is a listed real estate investment company (French SIIC), on Compartment A of Euronext Paris (ISIN FR0010481960 – ARG) and is included in the Euronext SBF 120, CAC All-Share, EPRA Europe and IEIF SIIC France indices.

www.argan.fr

Francis Albertinelli – CFO Aymar de Germay – General Secretary Samy Bensaid – Head of Investor Relations Phone: +33 1 47 47 47 40 E-mail: contact@argan.fr

Marlène Brisset – Media relations Phone: +33 6 59 42 29 35 E-mail: argan@cdrconsultancy.com

---

1 Indicative timetable, subject to change, in particular depending on the completion of the merger.

Attachment

• 20261019 – Merger report

Kenmare Resources plc
(“Kenmare” or the “Company” or the “Group”)

20 October 2026

Response to Mozambican media reports regarding Implementation Agreement

Kenmare Resources plc (LSE:KMR, ISE:KMR), one of the leading global producers of titanium minerals and zircon, which operates the Moma Titanium Minerals Mine (the “Mine” or “Moma”) in northern Mozambique, notes the recent reports in the Mozambican media regarding the finalisation of Moma’s Implementation Agreement (“IA”), following comments from a spokesman of the Government of Mozambique (the “Government”). The Company has not, to date, received any official confirmation or other correspondence on this matter from the Government. The Company is therefore unable to confirm the status or the terms of any renewal until it receives such confirmation or communication.

Kenmare remains committed to achieving a positive near-term conclusion of the IA renewal process and the Company will update the market of any developments as soon as possible.

Background on Implementation Agreement

The IA grants certain rights and concessions to Kenmare Moma Processing (Mauritius) Limited in connection with its processing and export activities. It also contains unambiguous renewal rights in relation to those rights and concessions on the same terms. Mining operations at Moma are conducted under a separate regulatory framework that is not impacted by the IA process.

Kenmare has been engaging with the Government on potential amendments to the applicable terms. Although the original expiry date was 21 December 2024, the Government provided confirmation that Kenmare’s existing rights and benefits remain in full force and effect pending conclusion of the extension process.

For further information, please contact:

Kenmare Resources plc
Katharine Sutton / David Weeks
Investor Relations
ir@kenmareresources.com
Tel: +353 1 671 0411
Mob: +353 87 663 0875 / +353 87 708 2525

Murray (PR advisor)
Paul O’Kane
pokane@murraygroup.ie
Tel: +353 1 498 0300
Mob: +353 86 609 0221

About Kenmare Resources

Kenmare Resources plc is one of the world’s largest producers of titanium minerals. Listed on the London Stock Exchange and the Euronext Dublin, Kenmare operates the Moma Titanium Minerals Mine in Mozambique. Moma’s production accounts for approximately 6% of global titanium feedstocks and the Company supplies to customers operating in more than 15 countries. Kenmare produces raw materials that are ultimately consumed in everyday quality-of-life items such as paints, plastics and ceramic tiles.

OSB GROUP PLC
ISIN: GB00BLDRH360
20 October 2026

LEI number: 213800ZBKL9BHSL2K459

OSB GROUP PLC (the “Company”)
Share Buyback Programme – Transactions in Own Shares and completion of buyback

The Company announces that on 19 October 2026 it had purchased a total of 75,220 of its ordinary shares of £0.01 each (the “ordinary shares“) on the London Stock Exchange, CBOE BXE ,CBOE CXE and Aquis Exchange, through the Company’s broker Jefferies International Limited as detailed below. The repurchased ordinary shares will be cancelled.

19 October 2026	London Stock Exchange	CBOE BXE	CBOE CXE	Aquis Exchange
Number of ordinary shares purchased	75,220	0	0	0
Highest price paid (per ordinary share)	492.20p	0.00p	0.00p	0.00p
Lowest price paid (per ordinary share)	485.00p	0.00p	0.00p	0.00p
Volume weighted average price paid (per ordinary share)	489.50p	0.00p	0.00p	0.00p

The purchases form part of the Company’s share buyback programme announced on 5 March 2026.

Following settlement of the above purchases and cancellation of the purchased ordinary shares, the Company’s total number of ordinary shares in issue shall be 335,357,246 ordinary shares.

No ordinary shares are held in treasury. Therefore, the total number of voting rights in the Company is 335,357,246 and may be used by shareholders (and others with notification obligations) as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

In accordance with Article 5(2)(b) of Regulation (EU) No 596/2024 as incorporated into and implemented under English law (including by virtue of the European Union (Withdrawal) Act 2028), the detailed breakdown of individual trades made by Jefferies International Limited on behalf of the Company as part of the share buyback programme is set out below.

The Company announces that, following the purchase of these shares, the share buy-back programme announced on 5 March 2026 has completed. Since the commencement of the buy-back, the Company has repurchased for cancellation 19,410,811 ordinary shares in aggregate at a volume weighted average price of 515.18p per ordinary share for a total consideration of approximately £100 million.

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

Schedule of Purchases

Issuer Name	OSB GROUP PLC
LEI	213800ZBKL9BHSL2K459
ISIN	GB00BLDRH360
Intermediary Name	Jefferies International Limited
Intermediary Code	JEFFGB2XXXX
Timezone	GMT
Currency	GBP

Individual Transactions:

Please see attached PDF for full list of transactions.

Attachment

• 2026.10.19_OSBG Buyback Fills

Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation

ZUG, Switzerland, October 20, 2026 — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at the 10^th Joint ACTRIMS-ECTRIMS Meeting (MSToronto 2026), on October 21-23, 2026, in Toronto, Canada.

The presentation will unveil new analyses evaluating circulating neuroaxonal and neuroinflammatory biomarkers, specifically plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP), in patients with acute optic neuritis (ON). These translational endpoints provide critical insight into acute central nervous system injury cascades and the biological rationale underlying neuroprotection.

The presentation will provide congress attendees, clinical investigators, members of the neuro-ophthalmology and multiple sclerosis communities with an opportunity to hear directly from Professor Céline Louapre, the principal investigator of the ACUITY Phase 2 trial, and discuss the new findings during the session.

Details of Oculis’ presentation at the ACTRIMS-ECTRIMS joint meeting are as follows:

      Presentation: Effect of Privosegtor on Plasma Neurofilament-Light and Glial Fibrillary Acidic Protein Levels in the Phase 2 ACUITY Trial in Optic Neuritis
      Presenter: Céline Louapre, M.D., Ph.D., Pitié-Salpêtrière Hospital
      Session: Late Breaking Abstracts
      Presentation ID: P1507
      Date/Time: Thursday, October 22, 2026; 4:30 – 6:30 p.m. EDT
      Location: Metro Toronto Convention Centre

“Optic neuritis and demyelinating relapses represent a high-stakes clinical race against permanent neuro-axonal loss and irreversible functional deficits such as visual impairments,” said Riad Sherif, M.D., Chief Executive Officer of Oculis. “With no approved neuroprotective therapies currently available to protect retinal ganglion cells and their axons, which transmit visual signals from the eye to the brain, deep translational analyses are vital to advancing care. At ECTRIMS, Professor Céline Louapre will present objective plasma biomarker readouts from the Phase 2 ACUITY trial, offering key insights into the biological pathways of optic neuritis and the neuroprotective potential of Privosegtor. We invite the international clinical and scientific community to join us for this late-breaking presentation as we work to advance the next frontier of neuroprotection.”

Following the successful Phase 2 ACUITY trial, Privosegtor was granted Breakthrough Therapy designation from the FDA and Priority Medicines (PRIME) designation from the EMA. Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program includes two registrational trials evaluating Privosegtor in patients with optic neuritis. The first trial, PIONEER-1, is currently enrolling patients with acute-onset ON across a broad population, including individuals with and without multiple sclerosis. Oculis plans to file an IND for Privosegtor in acute MS relapses. The Company will host an R&D Day on December 8, 2026, to provide updates on its differentiated late-stage pipeline, including Privosegtor and Licaminlimab.

– Ends –

About Privosegtor
Privosegtor, a novel peptoid small-molecule candidate that crosses the blood-brain and retinal barriers, has the potential to become the first neuroprotective therapy for optic neuritis (ON) and other neuro-ophthalmic and neuro-axonal diseases. Positive results from the ACUITY Phase 2 trial showed Privosegtor’s neuroprotective potential, as evidenced by improved visual function, corroborated by anatomical preservation of the retina, including the GCIPL and RNFL layers, and reduced neurofilament levels in the blood after an acute episode of optic neuritis. Consistent results were observed in animal models of glaucoma, optic neuritis, and multiple sclerosis (MS), where Privosegtor preserved retinal ganglion cells and was associated with improvements in mobility (clinical function disability) in the MS model.

Privosegtor has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) and Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) as well as Orphan Drug designation from both the FDA and the EMA for ON. Privosegtor is currently being evaluated in Oculis’ PIONEER (Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research) program, which includes two registrational trials in ON and one registrational trial in non-arteritic anterior ischemic optic neuropathy (NAION). Building on the ACUITY Phase 2 dataset in ON and constructive FDA pre-IND feedback, Oculis is also planning an IND submission for Privosegtor for the treatment of acute MS relapses.

Privosegtor is an investigational drug and has not received regulatory approval for commercial use in any country.

About Optic Neuritis

Optic Neuritis (ON) is a rare condition characterized by an acute inflammation of the optic nerve that can lead to permanent visual impairment. It affects up to 8 in 100,000 people worldwide with a U.S. annual incidence estimated to be >30,000 and often represents the first sign of multiple sclerosis^1,2. It mainly occurs in adults between the age of 20 and 40 years and is more frequent in women (2:1)³. ON is a type of neuropathy (nerve disease) that happens when acute inflammation of the optic nerve affects the signals traveling from the eyes through the brain, causing pain, vision loss and other symptoms. The cells that make up the optic nerve have a lipid protective coating called a myelin sheath, which is preferentially damaged in ON. Without myelin, the optic nerve cells can’t send signals properly and axons can be irreversibly lost. To date there is no specific therapy approved for acute optic neuritis and the unmet needs remain for therapies that can prevent vision loss after an acute episode by reducing nerve cell permanent damage or death.

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis’ highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNFα in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
        
For more information, please visit: www.oculis.com

Oculis Contact
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com
mailto:

Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations
ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements and information. For example, statements regarding the potential benefits of the Company’s product candidates, including the potential for Privosegtor to become the first neuroprotection therapy for optic neuritis and its potential broad applicability across neurology, including in acute MS relapses, the initiation, enrollment, timing, progress and results of current and future clinical trials, Oculis’ research and development programs, regulatory and business strategy; Oculis’ future development plans; the timing or likelihood of regulatory filings and approvals; and statements about market opportunity, are forward-looking. All forward-looking statements are based on estimates and assumptions that, while considered reasonable by Oculis and its management, are inherently uncertain and are inherently subject to risks, variability, and contingencies, many of which are beyond Oculis’ control. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by an investor as, a guarantee, assurance, prediction or definitive statement of a fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Results of earlier stage clinical trials may not be replicated in subsequent clinical trials. All forward-looking statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially from those that we expected and/or those expressed or implied by such forward-looking statements. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of Oculis, including those set forth in the Risk Factors section of Oculis’ annual report on Form 20-F and any other documents filed with the U.S. Securities and Exchange Commission (SEC). Copies of these documents are available on the SEC’s website, www.sec.gov. Oculis undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

References:

1. Martínez-Lapiscina EH, et al. (2014): Is the incidence of optic neuritis rising? Evidence from an epidemiological study in Barcelona (Spain) 2008-2012. J Neurol. 2014 Apr; 261(4): 759-767.
2. Pérez-Cambrodí RJ, Gómez-Hurtado Cubillana A, Merino-Suárez ML, Piñero-Llorens DP, Laria-Ochaita C. Optic neuritis in pediatric population: a review in current tendencies of diagnosis and management. J Optom. 2014 Jul-Sep;7(3):125-30.
3. Sing Hayreh S. (2008): Nonarteritic anterior ischemic optic neuropathy: natural history of visual outcome. Ophthalmology. 2088 Feb;115(2):298-305.

Please see below information about transactions made under the third tranche of the 2026 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO).

Date on which the buy-back tranche was announced: 22 July 2026.

The duration of the buy-back tranche: 23 July to no later than 26 October 2026.

Further information on the tranche can be found in the stock market announcement on its commencement dated 22 July 2026, available here: https://newsweb.oslobors.no/message/678529

From 12 October to 16 October 2026, Equinor ASA has purchased a total of 540,275 own shares at an average price of NOK 425.4849 per share.

Overview of transactions:

Date	Trading venue	Aggregated daily volume (number of shares)	Daily weighted average share price (NOK)	Total daily transaction value (NOK)
12 October	OSE	137,775	418.3224	57,634,368.66
	CEUX
	TQEX
13 October	OSE	137,500	420.9934	57,886,592.50
	CEUX
	TQEX
14 October	OSE	132,000	431.5169	56,960,230.80
	CEUX
	TQEX
15 October	OSE
	CEUX
	TQEX
16 October	OSE	133,000	431.5615	57,397,679.50
	CEUX
	TQEX
Total for the period	OSE	540,275	425.4849	229,878,871.46
	CEUX
	TQEX
Previously disclosed buy-backs under the tranche	OSE	7,697,832	396.5241	3,052,375,860.73
	CEUX
	TQEX
	Total	7,697,832	396.5241	3,052,375,860.73
Total buy-backs under the tranche (accumulated)	OSE	8,238,107	398.4234	3,282,254,732.19
	CEUX
	TQEX
	Total	8,238,107	398.4234	3,282,254,732.19

Following completion of the above transactions, Equinor ASA owns a total of 23,077,317 own shares, corresponding to 0.97% of Equinor ASA’s share capital, including shares under Equinor’s share savings programme (excluding shares under Equinor’s share savings programme, Equinor owns a total of 11,773,082 own shares, corresponding to 0.49% of the share capital).

This is information that Equinor ASA is obliged to make public pursuant to the EU Market Abuse Regulation and that is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Appendix: An overview of all transactions made under the buy-back tranche that have been carried out during the above-mentioned time period is attached to this report and available at www.newsweb.no.

Contact details:

Investor relations
Bård Glad Pedersen, senior vice president Investor Relations,
+47 918 01 791

Media
Sissel Rinde, vice president Media Relations,
+47 412 60 584

Attachment

• Detailed overview of transactions

THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

Ivry-sur-Seine – France, October 20, 2026, 7:30 AM CET

MERGER CONTROL CLEARANCE FROM THE EUROPEAN COMMISSION OF
THE TAKEOVER BID INITIATED BY EP GROUP

• Merger control clearance obtained by the European Commission
• Closing of the Offer expected beginning of November 2026

Fnac Darty and EP FR HOLDCo, a company controlled by EP Group and set up for the purposes of the proposed public tender offer for the outstanding shares and OCEANEs of Fnac Darty (the “Offer”) announce that they have received the merger control clearance from the European Commission for the planned acquisition of Fnac Darty.

As a result of the receipt of this decision, which constitutes the last expected approval of the transaction, the French Financial markets authority (Autorité des marchés financiers – AMF) will announce in the coming days the final timetable for the Offer, and in particular closing date of the tender Offer.

Terms and conditions of the Offer
The Offer price is €35 per share following payment on June 5, 2026 of the €1.0 dividend for the 2025 financial year, and €81.16¹ per OCEANE.

The Offer was approved on May 7, 2026 by the AMF, which granted its visa on the offer document of EP FR HOLDCo under number 26-128, and on Fnac Darty’s response document under number 26-129.

The Board of Directors of Fnac Darty, on the recommendation of the Ad Hoc Committee, has issued a favorable opinion on the Offer detailed in the response document of Fnac Darty.

Ledouble, acting as an independent expert, has issued a report stating that the financial conditions of the Offer are fair for Fnac Darty’s shareholders and OCEANE holders.

The documentation linked to the Offer is available on Fnac Darty’s website in the dedicated section (https://www.fnacdarty.com/en/group/investors/projet-doffre-publique-dachat-de-ep-group/) as well as on the AMF website (www.amf-france.org).

        

Disclaimer
This press release has been prepared for informational purposes only. It does not constitute an offer to buy or a solicitation for the sale of Fnac Darty shares in any country, including France. The dissemination, publication or distribution of this press release may be subject to specific regulations or restrictions in certain countries. Accordingly, persons in possession of this notice are required to inform themselves of any local restrictions that may apply and to comply with them. Fnac Darty excludes any liability in the event of violation of applicable legal restrictions by any person.

About Fnac Darty

Fnac Darty is a European leader in omnichannel retail, a leading player in the sale of consumer electronics, household appliances, cultural and leisure goods. Present in 15 countries, mainly in France, Italy, Belgium, Portugal, Spain and Switzerland, it has nearly 30,000 employees and a multi-format network of around 1,500 stores, with strong positions on the web and a growing number of subscribers to its services. In 2025, the Group recorded sales of more than €10 billion. With Beyond everyday, its strategic plan for 2030, Fnac Darty is continuing its expansion in Europe and deepening its model based on omnichannel, services and circularity.
For more information: www.fnacdarty.com

CONTACTS
ANALYSTS/INVESTORS
Domitille Vielle – Head of Investor Relations – domitille.vielle@fnacdarty.com – +33 (0)6 03 86 05 02
Laura Parisot – Investor Relations Manager – laura.parisot@fnacdarty.com – +33 (0)6 64 74 27 18

PRESS
Bénédicte Debusschere – Head of Corporate Communications – benedicte.debusschere@fnacdarty.com – +33 (0)6 48 56 70 71

---

1 Assuming an interest period starting on March 23, 2026 and ending on November 12, 2026, as illustrative settlement date of the initial acceptance period of the offer.

Attachment

• 20261020_PR_EC clearance_MEL

THE DISSEMINATION, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IS NOT AUTHORIZED IN THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, JAPAN OR ANY OTHER COUNTRY WHERE SUCH COMMUNICATION WOULD VIOLATE APPLICABLE REGULATIONS

Ivry-sur-Seine – France, October 20, 2026, 7:30 AM CET

MERGER CONTROL CLEARANCE FROM THE EUROPEAN COMMISSION OF
THE TAKEOVER BID INITIATED BY EP GROUP

• Merger control clearance obtained by the European Commission
• Closing of the Offer expected beginning of November 2026

Fnac Darty and EP FR HOLDCo, a company controlled by EP Group and set up for the purposes of the proposed public tender offer for the outstanding shares and OCEANEs of Fnac Darty (the “Offer”) announce that they have received the merger control clearance from the European Commission for the planned acquisition of Fnac Darty.

As a result of the receipt of this decision, which constitutes the last expected approval of the transaction, the French Financial markets authority (Autorité des marchés financiers – AMF) will announce in the coming days the final timetable for the Offer, and in particular closing date of the tender Offer.

Terms and conditions of the Offer
The Offer price is €35 per share following payment on June 5, 2026 of the €1.0 dividend for the 2025 financial year, and €81.16¹ per OCEANE.

The Offer was approved on May 7, 2026 by the AMF, which granted its visa on the offer document of EP FR HOLDCo under number 26-128, and on Fnac Darty’s response document under number 26-129.

The Board of Directors of Fnac Darty, on the recommendation of the Ad Hoc Committee, has issued a favorable opinion on the Offer detailed in the response document of Fnac Darty.

Ledouble, acting as an independent expert, has issued a report stating that the financial conditions of the Offer are fair for Fnac Darty’s shareholders and OCEANE holders.

The documentation linked to the Offer is available on Fnac Darty’s website in the dedicated section (https://www.fnacdarty.com/en/group/investors/projet-doffre-publique-dachat-de-ep-group/) as well as on the AMF website (www.amf-france.org).

        

Disclaimer
This press release has been prepared for informational purposes only. It does not constitute an offer to buy or a solicitation for the sale of Fnac Darty shares in any country, including France. The dissemination, publication or distribution of this press release may be subject to specific regulations or restrictions in certain countries. Accordingly, persons in possession of this notice are required to inform themselves of any local restrictions that may apply and to comply with them. Fnac Darty excludes any liability in the event of violation of applicable legal restrictions by any person.

About Fnac Darty

Fnac Darty is a European leader in omnichannel retail, a leading player in the sale of consumer electronics, household appliances, cultural and leisure goods. Present in 15 countries, mainly in France, Italy, Belgium, Portugal, Spain and Switzerland, it has nearly 30,000 employees and a multi-format network of around 1,500 stores, with strong positions on the web and a growing number of subscribers to its services. In 2025, the Group recorded sales of more than €10 billion. With Beyond everyday, its strategic plan for 2030, Fnac Darty is continuing its expansion in Europe and deepening its model based on omnichannel, services and circularity.
For more information: www.fnacdarty.com

CONTACTS
ANALYSTS/INVESTORS
Domitille Vielle – Head of Investor Relations – domitille.vielle@fnacdarty.com – +33 (0)6 03 86 05 02
Laura Parisot – Investor Relations Manager – laura.parisot@fnacdarty.com – +33 (0)6 64 74 27 18

PRESS
Bénédicte Debusschere – Head of Corporate Communications – benedicte.debusschere@fnacdarty.com – +33 (0)6 48 56 70 71

---

1 Assuming an interest period starting on March 23, 2026 and ending on November 12, 2026, as illustrative settlement date of the initial acceptance period of the offer.

Attachment

• 20261020_PR_EC clearance_MEL

•  Highlights include oral presentations of pediatric data from the fosmanogepix Expanded Access Program and the activity of its active moiety, manogepix, against Candida auris isolates

Allschwil, Switzerland, October 20, 2026

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that new data on the phase 3 antifungal fosmanogepix, the antifungal isavuconazole (Cresemba^®) and the antibiotic ceftobiprole (Zevtera^®) will be presented at IDWeek 2026, which takes place from October 21 to 24 in Washington D.C., USA.

Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “The breadth of data being presented at IDWeek across Basilea’s anti-infectives portfolio by us, our partners, collaborators and independent research groups, underscores the strong scientific interest in advancing the treatment of serious fungal and bacterial infections. These presentations continue to strengthen the evidence supporting our programs and their potential to address important unmet medical needs, including for pediatric patients.”

Fosmanogepix data presented at IDWeek 2026
–	Presentation: Fosmanogepix Expanded Access Experience in Pediatric Patients ≤11 Years of Age with Invasive Mold Infections Presenting author: L. E. Hastings Co-authors: K. L. Barros, M. L. Kussin, M. A. Kutny, J. B. Wood, Y. Vipulanandan, R. Banerjee, D. Dulek, T. S. Sharma, E. Kang, S. Maxwell, A. M. Green, D. Tyungu, M. M. Oldham, J. G. Lake, G. R. Alvira-Arill, E. Kitt, P. Gavin, N. DV De León, Y. Mozo del Castillo, E. Iosifidis, E. Roilides, D. S. Kohlfürst, J. Prattes, M. Hoenigl, O. O’Connor, J. Ryan, A. Howard-Jones, N. Maissen, V. A. Cruz Flores, H. Schlamm, K. Litherland, D. Ionescu, M. Engelhardt, E. Steletou, L. M. Kirkpatrick, J. C. Christenson, P. G. Pappas Date & time: Friday, October 23, 2026, 10:42-10:54 am Location: 201
–	Presentation: Activity of manogepix against Candida auris isolates from the United States Presenting author: M. Winkler Co-authors: A. Klauer, S. Edeker, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira Date & time: Friday, October 23, 2026, 4:15-4:30 pm Location: 103 AB
–	Poster #P-17: Activity of manogepix against Aspergillus spp. isolates with CYP51 alterations Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Karr, H. Kimbrough, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-18: Activity of manogepix against mold isolates across geographic regions Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-19: Activity of manogepix against yeast and mold isolates from 2025 in the United States Presenting author: M. Winkler Co-authors: S. Edeker, A. Klauer, P. Rhomberg, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C

Isavuconazole data presented at IDWeek 2026
–	Rapid-Fire Poster Session: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients [see also Poster #P-2022] Rapid Fire presenters: M. A. Colaluca, K. Marsh, Y. Li, C. Otto, M. Ringer Date & time: Friday, October 23, 2026, 12:30-12:35 pm Location: RF Arena 1
–	Poster #P-31: Hepatotoxicity Signals Across Azole Antifungals: Is Isavuconazole Safer? A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Presenting author: V. Thiruvadi Co-authors: R. Ravichandran, Y. Kagzi, S. Ahsan, M. Alqaisieh, M. Kandula, D. Francisco Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Virtual Presentation
–	Poster #P-1645: Adoption of Isavuconazole in Pediatrics: A Multi-Center Survey Presenting author: C. Lan Co-authors: H. A. Jamal, M. Johnson, S. Vora Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-1922: Evaluation of Inpatient Isavuconazole Prescribing Practices at a Community-Based Cancer Center Presenting author: W. Monier Texidor Co-authors: S. Kim, J. Unzaga, A. Ramos Morales, L. Kemp, L. Amaya Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-2005: Invasive aspergillosis in kidney transplant recipients: A 20-year cohort from Colombia Presenting author: I. Ramirez Co-author: C. Ruiz Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Virtual presentation
–	Poster #P-2018: Epidemiology of Invasive Fungal Disease in Allogeneic Hematopoietic Cell Transplant Recipients at a Brazilian Cancer Center (2012–2022): Preliminary Data Presenting author: M. V. Batista Co-authors: A. Volpe, E. Veras; T. Monteiro-Silva, A. Luiza Marinho, B. Cal, A. Cordeiro, V. Bovolenta, M. Nascimento, J. Schmidt-Filho Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-2022: Isavuconazole versus Alternative Azoles for Invasive Aspergillus in Solid Organ Transplant Recipients Presenting author: M. A. Colaluca Co-authors: K. Marsh, Y. Li, C. Otto, M. Ringer Date & time: Friday, October 23, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-1372: Nationwide Retrospective Analysis of Isavuconazole Treatment for Histoplasmosis Presenting author: C. A. Gentry Co-authors: J. J. Farha, S. Thind, R. Williams, II Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-1378: Effectiveness and Safety of Isavuconazole Compared with Posaconazole as Primary Antifungal Prophylaxis in High-risk Neutropenic Patients with Hematologic Malignancies and Allogeneic Hematopoietic Cell Transplantation Presenting author: F. Herrera Co-authors: D. Torres, N. Mañez, R. Jordán, J. Benso, M. Angel Alderete, Sr., N. Garcia Allende, G. A. Mendez, Sr., M. L. Pereya, L. Tula, A. Manzur, H. I. Peretti, El, C. Salgueira, M. Rodríguez Raimondo, F. Indo, S. Garcia Rojas, P. Callelo, M. Gabriel Castro, V. Fernandéz, A. Risso Patron, C. Niveyro, R. Gago, L. A. Luengo Ackermann, J. Afeltra Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C

 

Ceftobiprole data presented at IDWeek 2026
–	Poster #P-36: Pediatric Dose Selection of Ceftobiprole for Staphylococcus aureus Bacteremia, Including Right-Sided Infective Endocarditis Using Model-Based Approaches Presenting author: A. Tanudra Co-authors: C. Lim, K. Rana, C. M. Rubino, D. Lewis, K. B. Larson Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-142: In vitro Activity of Ceftobiprole and Comparator Agents Against Contemporary US Clinical Isolates Collected in 2025 Following FDA Approval Presenting author: R. E. Mendes Co-authors: M. Winkler, S. H. Moussa, T. Wiktorowicz, H. Sader, M. Castanheira Date & time: Thursday, October 22, 2026, 12:15-1:30 pm Location: Poster Hall B-C
–	Poster #P-381: Extrapolation of Adult Efficacy and Safety to Support Pediatric Use of Ceftobiprole for Acute Bacterial Skin and Skin Structure Infections Presenting author: K. B. Larson Co-authors: R. Tummala, N. C. Close, C. M. Rubino, K. Rana, C. Lim, A. Tanudra, S. McLeod, S. Rege, D. Altarac, D. Lewis Date & time: Saturday, October 24, 2026, 12:15-1:30 pm Location: Poster Hall B-C

For further information please visit www.idweek.org. 

The fosmanogepix development program is funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration of Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under OT number: 75A50124C00033. The agreement and federal funding are not an endorsement of study results, product, or company.

For Cresemba^® (isavuconazonium sulfate)¹ full U.S. prescribing information, please visit: https://www.astellas.us/docs/cresemba.pdf 

For ZEVTERA^® (ceftobiprole medocaril sodium)² full U.S. prescribing information, please visit: https://www.zevtera.com/pi 

Basilea’s ceftobiprole phase 3 program was funded in part with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201600002C. The contract and federal funding are not an endorsement of the study results, product, or company. Basilea was awarded approximately USD 111 million, or approximately 75 percent of the costs related to the Staphylococcus aureus bacteremia (SAB) and acute bacterial skin and skin structure infections (ABSSSI) phase 3 studies, regulatory activities and non-clinical work.

About Basilea

Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. 

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements, such as “believe”, “assume”, “expect”, “forecast”, “project”, “may”, “could”, “might”, “will” or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland
Phone	+41 61 606 1102
E-mail	media_relations@basilea.com  investor_relations@basilea.com

This press release can be downloaded from www.basilea.com. 

References

1. Astellas Pharma Inc. is the organization responsible for commercializing Cresemba in the U.S.
2. Innoviva Specialty Therapeutics is the organization responsible for commercializing Zevtera in the U.S.

Attachment

• Press release (PDF)